ERBB2 and breast carcinoma: The binding properties of the HER2 mAb and HER2-ACC were determined via flow cytometry in various cancer cell lines with different levels of HER2 expression, including BT-474 and KPL-4 breast cancer and Calu-3 lung cancer cells (Table 1, Figure 1C–E).